Informatie:
Fout:
ID
34157
Beschrijving
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01363986
Link
https://clinicaltrials.gov/show/NCT01363986
Trefwoorden
Versies (1)
- 14-01-19 14-01-19 -
Houder van rechten
see on clinicaltrials.gov
Geüploaded op
14 januari 2019
DOI
Voor een aanvraag inloggen.
Licentie
Creative Commons BY 4.0
Model Commentaren :
Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.
Itemgroep Commentaren voor :
Item Commentaren voor :
U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.
Eligibility Breast Cancer NCT01363986
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
diagnosis of breast carcinoma with her-2 overexpression
boolean
ID.3
Item
at least one measurable brain metastasis
boolean
ID.4
Item
patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option
boolean
ID.5
Item
performance status (who) </=2
boolean
ID.6
Item
life expectancy >/=3 months
boolean
ID.7
Item
presence of neoplastic meningitis
boolean
ID.8
Item
any prior radiotherapy to the brain
boolean
ID.9
Item
patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option
boolean
ID.10
Item
previous neoplasms, other than breast carcinoma, within 5 years since enrolment
boolean